Patent Registration Completed For SELBEX Gastritis Use Treatment
Tokyo (September 30, 1998) - Eisai Co., Ltd. of Tokyo (President and CEO: Haruo Naito) today announced that procedures for the patent registration for SELBEX (teprenone) use for the treatment of gastritis have been completed. The Japanese Patent Office rejected other claims regarding this registration.
Since registration procedures have been completed, the patent will be officially registered around October 10. The patent will be valid until July, 2005.
As soon as the patent is officially registered, Eisai will take legal action against manufacturers or sellers infringing on this patent.
Eisai Co., Ltd. is a research-based human health care company which discovers, develops and markets products in more than 30 countries. Through its global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of worldwide health care systems. The company reported sales of about $2.3 billion in 1997 with approximately 15 percent of sales spent for research and development.
SELBEX is a trademark of Eisai Co., Ltd.